Subtopic Deep Dive
Ruxolitinib Therapy in Myelofibrosis
Research Guide
What is Ruxolitinib Therapy in Myelofibrosis?
Ruxolitinib therapy in myelofibrosis is the FDA-approved JAK1/2 inhibitor treatment targeting spleen volume reduction, symptom alleviation, and survival improvement in primary myelofibrosis patients.
Ruxolitinib demonstrates durable spleen response and symptom control in phase 3 COMFORT-I trial over 5 years (Verstovšek et al., 2017, 417 citations). It addresses constitutional symptoms measured by MPN-SAF TSS (Emanuel et al., 2012, 438 citations). Resistance mechanisms involve JAK/STAT pathway alterations (Quintás-Cardama and Verstovšek, 2013, 276 citations).
Why It Matters
Ruxolitinib sets the standard for targeted therapy in myelofibrosis, reducing spleen size by ≥35% in 41.9% of patients at 6 months and improving survival compared to conventional care (Verstovšek et al., 2017). It enhances quality of life by alleviating debilitating symptoms like fatigue and pruritus, validated via MPN-SAF TSS (Emanuel et al., 2012). European LeukemiaNet guidelines recommend it as first-line for intermediate-2 or high-risk disease (Barbui et al., 2018). Long-term data inform switching strategies, as seen in pacritinib trials (Mascarenhas et al., 2018).
Key Research Challenges
Drug Resistance Development
Ruxolitinib resistance emerges from JAK2 V617F allele burden persistence and secondary mutations (Quintás-Cardama and Verstovšek, 2013). Patients lose spleen response after 1-2 years despite initial benefits (Verstovšek et al., 2017). Alternative inhibitors like pacritinib show activity post-ruxolitinib failure (Mascarenhas et al., 2018).
Survival Benefit Confirmation
Phase 3 trials confirm spleen and symptom responses but require molecular prognostic models for survival prediction (Passamonti et al., 2017). Anemia worsens in 20-30% of patients during therapy (Verstovšek et al., 2017). WHO classifications update diagnostic criteria impacting trial eligibility (Arber et al., 2016).
Symptom Burden Quantification
MPN-SAF TSS validates symptom scoring but needs integration with molecular markers like CALR mutations (Emanuel et al., 2012; Fučíková et al., 2020). Patient-reported outcomes vary across post-PV/ET MF subtypes (Passamonti et al., 2017). Standardized assessment aids therapy comparison (Barbui et al., 2018).
Essential Papers
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian et al. · 2016 · Blood · 10.0K citations
Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identi...
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury, Éric Solary, Oussama Abla et al. · 2022 · Leukemia · 3.5K citations
The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing Li, Maorong Fu et al. · 2021 · Signal Transduction and Targeted Therapy · 2.2K citations
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Sally Thomas, John A. Snowden, Martin P. Zeidler et al. · 2015 · British Journal of Cancer · 626 citations
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi et al. · 2018 · Leukemia · 537 citations
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel, Amylou C. Dueck, Holly L. Geyer et al. · 2012 · Journal of Clinical Oncology · 438 citations
Purpose Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapie...
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · 2017 · Journal of Hematology & Oncology · 417 citations
Reading Guide
Foundational Papers
Start with Emanuel et al. (2012) for MPN-SAF TSS symptom validation and Quintás-Cardama and Verstovšek (2013) for JAK/STAT resistance mechanisms, providing baseline for ruxolitinib evaluation.
Recent Advances
Study Verstovšek et al. (2017) COMFORT-I update for long-term outcomes and Mascarenhas et al. (2018) pacritinib trial for post-ruxolitinib strategies.
Core Methods
JAK1/2 inhibition measured by spleen volumetry (MRI/CT), MPN-SAF TSS scoring, and molecular monitoring of JAK2 V617F allele burden (Verstovšek et al., 2017; Emanuel et al., 2012).
How PapersFlow Helps You Research Ruxolitinib Therapy in Myelofibrosis
Discover & Search
Research Agent uses searchPapers and citationGraph on 'ruxolitinib myelofibrosis' to map 417-cited COMFORT-I update (Verstovšek et al., 2017) connected to 438-cited MPN-SAF (Emanuel et al., 2012), revealing resistance papers via findSimilarPapers.
Analyze & Verify
Analysis Agent applies readPaperContent to extract 5-year survival data from Verstovšek et al. (2017), verifies claims with CoVe against Arber et al. (2016) WHO criteria, and runs PythonAnalysis on MPN-SAF TSS datasets for statistical significance using GRADE evidence grading.
Synthesize & Write
Synthesis Agent detects gaps in resistance mechanisms post-ruxolitinib via contradiction flagging across Quintás-Cardama (2013) and Mascarenhas (2018); Writing Agent uses latexEditText, latexSyncCitations for trial comparison tables, and latexCompile for publication-ready reviews with exportMermaid for JAK/STAT pathway diagrams.
Use Cases
"Analyze survival curves from COMFORT-I ruxolitinib data"
Research Agent → searchPapers('Verstovšek 2017') → Analysis Agent → readPaperContent + runPythonAnalysis (pandas survival plots, Kaplan-Meier stats) → matplotlib output with p-values.
"Draft LaTeX review on ruxolitinib vs pacritinib in MF"
Synthesis Agent → gap detection (Mascarenhas 2018, Verstovšek 2017) → Writing Agent → latexEditText (structure sections) → latexSyncCitations → latexCompile → PDF with embedded tables.
"Find code for MPN symptom scoring models"
Research Agent → searchPapers('Emanuel 2012 MPN-SAF') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect (TSS calculation scripts) → runPythonAnalysis sandbox execution.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ ruxolitinib papers: searchPapers → citationGraph → DeepScan (7-step verify with CoVe checkpoints on survival data from Verstovšek 2017). Theorizer generates hypotheses on resistance from Quintás-Cardama (2013) + Hu (2021) JAK/STAT synthesis. DeepScan analyzes symptom trajectories with Python sandbox on Emanuel (2012) datasets.
Frequently Asked Questions
What defines ruxolitinib therapy in myelofibrosis?
Ruxolitinib is a JAK1/2 inhibitor approved for intermediate-2 or high-risk myelofibrosis, achieving ≥35% spleen volume reduction in 41.9% of COMFORT-I patients (Verstovšek et al., 2017).
What methods assess ruxolitinib efficacy?
Spleen response by MRI/CT volumetry and symptoms via MPN-SAF TSS, validated in international cohorts (Emanuel et al., 2012; Verstovšek et al., 2017).
What are key papers on ruxolitinib?
COMFORT-I 5-year update (Verstovšek et al., 2017, 417 citations) and resistance mechanisms (Quintás-Cardama and Verstovšek, 2013, 276 citations); guidelines in Barbui et al. (2018).
What open problems exist?
Overcoming resistance via next-gen inhibitors (Mascarenhas et al., 2018) and confirming OS benefit independent of spleen response (Passamonti et al., 2017).
Research Myeloproliferative Neoplasms: Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Ruxolitinib Therapy in Myelofibrosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers